Translational Development Acquisition Corp.

Translational Development Acquisition Corp. (Nasdaq: TDAC) is a blank-check company targeting the life sciences and healthcare sector, with a focus on translational medicine — the bridge between early-stage scientific research and commercial therapeutic applications. The company filed an amended S-1/A registration statement with the SEC on December 19, 2024, under accession number 0001104659-24-129831, indicating the SPAC was in the registration process heading into its IPO. The name reflects a thesis centered on companies advancing clinical-stage or near-commercial healthcare innovations. Sign up for a free SpacDesk account to access TDAC's full filing history, deal timelines, and sponsor data in one place.